Is Lucentis (ranibizumab) Effective in Treating CRVO?
August 3, 2009
Results of Genetech’s CRUISE trial indicate that ranibizumab is safe and effective for treatment of macular edema secondary to CRVO. The study involved ranibizumab injections vs. sham injections followed by a 6 month observation period. Results indicate that the ranibizumab group realized improved vision and the results were maintained.
The CRUISE data is consistent with earlier released BRAVO trial data indicating that macular edema from BRVO can be effectively treated with ranibizumab. The complete results of both studies are scheduled to be released at the upcoming Retina Congress.
Read the article.
Randall V. Wong, M.D.
You might also enjoy...
- Lucentis Approved in Europe to Treat Patients With Macular Edema Secondary to Retinal Vein Occlusion
- Are Intravitreal Injections of Lucentis Effective In Improving Macular Edema Caused by BRVO/CRVO?
- Lucentis Improves Vision in Retinal Vein Occlusions
- Lucentis Shown Effective in Treating Diabetic Macular Edema in Second Trial
- Is Avastin Better for CSME?
Jump down to form below to submit your own comments